Ensuring Transparency: How to Disclose Conflicts of Interest in Clinical Trial Publications

Introduction: Why Conflict of Interest (COI) Disclosures Matter

Conflict of Interest (COI) disclosures are a cornerstone of clinical research transparency. Whether financial or non-financial, real or perceived, any interest that may influence—or appear to influence—the interpretation, reporting, or publication of trial results must be declared. Failure to do so not only undermines scientific credibility but can lead to public mistrust, regulatory sanctions, and journal retractions.

Organizations like the International Committee of Medical Journal Editors (ICMJE) and regulatory authorities have set strict expectations for COI declarations. This tutorial outlines what to disclose, how to declare it, and how to manage conflicts to maintain research integrity.

Defining Conflicts of Interest in Clinical Research

A conflict of interest occurs when personal, financial, professional, or institutional affiliations could compromise, or appear to compromise, an individual’s objectivity. COIs in clinical research typically fall into the following categories:

• Financial: Payments from sponsors, stock ownership, patents, speaker fees, consultancy income, etc.
• Professional: Editorial board roles, grant reviewer positions, or leadership in advocacy groups
• Personal: Family or close relationships with trial sponsors or competitors
• Institutional: Trial conducted at an organization receiving funding from the study sponsor

Transparency does not imply wrongdoing. Rather, it enables readers and regulators to fairly interpret the findings.

ICMJE Disclosure Requirements

Most major medical journals follow ICMJE recommendations, which require all authors to complete a standardized disclosure form. Key elements of the form include:

• Grants or contracts from any entity (past 36 months)
• Royalties or licenses
• Consulting fees or honoraria
• Payment for lectures or educational events
• Expert testimony payments
• Stock or stock options
• Travel or meeting support
• Leadership roles in boards, societies, or committees

The ICMJE form must be updated at the time of submission and reflects relationships over the past three years. Some journals publish the full form as supplementary material.

Disclosure Practices by Journals

While ICMJE provides the framework, individual journals may have additional requirements:

• The BMJ: Requires narrative COI disclosures within the manuscript
• The Lancet: Publishes author COI statements and funding sources in a dedicated section
• PLOS: Uses its own disclosure form and requires data availability and COI confirmation
• NEJM: Publishes COIs prominently and requires rigorous editorial checks

Authors should consult the “Instructions for Authors” on journal websites to comply fully with formatting and wording standards.

COI in Industry-Sponsored Trials

In industry-sponsored trials, COIs are more prevalent due to financial relationships between investigators and sponsors. Best practices include:

• Separating data analysis from the sponsor’s influence
• Declaring sponsor involvement in protocol design, analysis, and manuscript preparation
• Clarifying authorship criteria and contribution of medical writers, if any

Medical journals often require authors to affirm that they had full access to data and responsibility for publication decisions.

Examples of Effective COI Statements

Clear, concise, and honest COI statements build credibility. Here are a few examples:

• “Dr. Smith has received research funding from ABC Pharma and served on their advisory board within the past 24 months.”
• “Ms. Jones is a full-time employee and shareholder of XYZ Biotech.”
• “The authors declare no competing interests.”

Ambiguity—such as “support from various companies”—should be avoided. Specific names and roles must be disclosed.

Managing Conflicts Internally

Clinical trial teams and sponsors should have internal policies and SOPs for managing COI, including:

• Annual COI declarations for all study personnel
• Training on what constitutes a COI
• COI review by an independent ethics committee or compliance office

Having a mitigation plan in place strengthens ethical oversight and prepares organizations for audits or inspections.

Impact of Non-Disclosure: Case Studies

Failure to disclose COI can lead to serious consequences. In 2021, a prominent investigator failed to declare stock holdings in a biotech firm whose drug he was testing. The journal retracted the article, and regulatory bodies launched investigations. In another case, ghostwriting by pharma companies led to litigation and reputational damage.

These cases emphasize that transparency is not optional—it is fundamental to ethical and legal compliance.

COI and Global Regulatory Expectations

Regulatory authorities such as the U.S. FDA, EMA, and Health Canada require financial disclosure from clinical investigators as part of marketing authorization applications:

• FDA Form 3454/3455: Documents financial interest in trials submitted in NDAs/BLAs
• EMA Module 1: Includes sponsor statements on financial disclosure and trial independence
• India CDSCO: Seeks declaration of independence and non-involvement in commercial bias

Regulators may question data validity if COIs are not properly managed or disclosed during clinical development.

Conclusion: Disclosure is Ethics in Action

Conflict of interest disclosures are not a bureaucratic hurdle—they are a declaration of ethical accountability. Transparent COI reporting supports evidence credibility, reader trust, and regulatory compliance. As global expectations grow stricter, research teams must institutionalize best practices in COI management from trial start to publication.

Disclosing conflicts does not discredit findings; hiding them does. Ethical research communicates fully, honestly, and proactively.